Benjamin Diamond

Benjamin Diamond

Auto-generated profile, based on publicly available information

Benjamin Diamond

Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
FMFrancesco Maura
Francesco Maura
ARArjun Raj Rajanna
Arjun Raj Rajanna
BZBachisio Ziccheddu
Bachisio Ziccheddu
APAlexandra M. Poos
Alexandra M. Poos
ADAndriy Derkach
Andriy Derkach
OLOla Landgren
Ola Landgren
PURPOSE: Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS: To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS: Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION: Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.

25 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BOBénedith Oben
Bénedith Oben
GFGuy Froyen
Guy Froyen
KMKylee H. Maclachlan
Kylee H. Maclachlan
DLDaniel Leongamornlert
Daniel Leongamornlert
FAFederico Abascal
Federico Abascal
FMFrancesco Maura
Francesco Maura
Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate the whole genome sequence (WGS) profile of 18 MGUS and compare them with those from 14 SMMs and 80 MMs. We show that cases with a non-progressing, clinically stable myeloma precursor condition (n = 15) are characterized by later initiation in the patient’s life and by the absence of myeloma defining genomic events including: chromothripsis, templated insertions, mutations in driver genes, aneuploidy, and canonical APOBEC mutational activity. This data provides evidence that WGS can be used to recognize two biologically and clinically distinct myeloma precursor entities that are either progressive or stable.

1 November 2020 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EREven H. Rustad
Even H. Rustad
VYVenkata D. Yellapantula
Venkata D. Yellapantula
DGDominik Glodzik
Dominik Glodzik
KMKylee H. Maclachlan
Kylee H. Maclachlan
BDBenjamin Diamond
Benjamin Diamond
FMFrancesco Maura
Francesco Maura
The landscape of structural variants (SV) in multiple myeloma remains poorly understood. Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with multiple myeloma by low-coverage long-insert whole-genome sequencing. We identified 68 SV hotspots involving 17 new candidate driver genes, including the therapeutic targets BCMA (TNFRSF17), SLAM7, and MCL1. Catastrophic complex rearrangements termed chromothripsis were present in 24% of patients and independently associated with poor clinical outcomes. Templated insertions were the second most frequent complex event (19%), mostly involved in super-enhancer hijacking and activation of oncogenes such as CCND1 and MYC. Importantly, in 31% of patients, two or more seemingly independent putative driver events were caused by a single structural event, demonstrating that the complex genomic landscape of multiple myeloma can be acquired through few key events during tumor evolutionary history. Overall, this study reveals the critical role of SVs in multiple myeloma pathogenesis. Significance: Previous genomic studies in multiple myeloma have largely focused on single-nucleotide variants, recurrent copy-number alterations, and recurrent translocations. Here, we demonstrate the crucial role of SVs and complex events in the development of multiple myeloma and highlight the importance of whole-genome sequencing to decipher its genomic complexity. See related commentary by Bergsagel and Kuehl, p. 221. This article is highlighted in the In This Issue feature, p. 215

19 December 2024 in Blood
Verified
Journal Article
Open access
HLHolly Lee
Holly Lee
MDMichael Durante
Michael Durante
SSSheri Skerget
Sheri Skerget
DVDeeksha Vishwamitra
Deeksha Vishwamitra
SBSacha Benaoudia
Sacha Benaoudia
NBNizar J. Bahlis
Nizar J. Bahlis
Adoptive T-cell therapy is a promising therapy for multiple myeloma (MM), but its efficacy hinges on understanding the relevant biologic and predictive markers of response. B-cell maturation antigen (BCMA) is a key target antigen in MM with active development of multiple anti-BCMA T-cell engagers (TCEs) and chimeric antigen receptor T-cell therapies. The regulation of surface BCMA expression by MM cells, which leads to shedding of soluble BCMA (sBCMA), has triggered debate about the significance of sBCMA as a predictive marker and its potential impact on treatment outcomes. To address this, we leveraged whole-genome sequencing and in vitro assays to demonstrate that sBCMA may independently predict primary refractoriness to anti-BCMA therapies. In addition to sBCMA, tumor burden and surface BCMA antigen density collectively influenced the anti-BCMA TCE cytotoxic efficacy. Correlative analyses of 163 patients treated with the anti-BCMA TCE teclistamab validated and further underscored the association between elevated baseline sBCMA (>400 ng/mL) and refractoriness. Importantly, increasing the TCE dose, using TCE against alternative targets (eg, GPRC5D), and gamma secretase inhibitors were able to overcome the high sBCMA levels. These findings highlight the importance of taking into account the baseline sBCMA levels, disease burden, and TCE dose intensity when administering anti-BCMA TCEs, thereby offering critical insights for optimizing therapeutic strategies to overcome specific high-risk features and primary anti-BCMA TCE refractoriness.

9 November 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
FMFrancesco Maura
Francesco Maura
EBEileen M. Boyle
Eileen M. Boyle
DCDavid Coffey
David Coffey
KMKylee Maclachlan
Kylee Maclachlan
DGDylan Gagler
Dylan Gagler
OLOla Landgren
Ola Landgren

19 May 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
FMFrancesco Maura
Francesco Maura
NWNiels Weinhold
Niels Weinhold
BDBenjamin Diamond
Benjamin Diamond
DKDickran Kazandjian
Dickran Kazandjian
Leo RascheLeo Rasche
Leo Rasche
OLOla Landgren
Ola Landgren